Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP13737808A	2021-01-08	Galenicum Health S.L.U.	Granted and Under Opposition
EP13737808A	2021-01-07	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP13737808A	2021-01-07	Generics [UK] Limited	Granted and Under Opposition
EP06725149A	2011-05-04	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8129343	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8536122	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122	NOVO	Acylated GLP-1 compounds	Mar, 2026 (1 year, 10 months from now)
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003	NOVO	Use of long-acting GLP-1 peptides	Jun, 2033 (9 years from now)
US10888605	NOVO	GLP-1 compositions and uses thereof	Aug, 2038 (14 years from now)
US11752198	NOVO	GLP-1 compositions and uses thereof	Aug, 2038 (14 years from now)
US11318191	NOVO	GLP-1 compositions and uses thereof	Feb, 2041 (16 years from now)

Wegovy is owned by Novo.

Wegovy contains Semaglutide.

Wegovy has a total of 6 drug patents out of which 0 drug patents have expired.

Wegovy was authorised for market use on 04 June, 2021.

Wegovy is available in solution;subcutaneous dosage forms.

Wegovy can be used as method for weight management, method for weight management according to a dose escalation schedule.

Drug patent challenges can be filed against Wegovy from 05 December, 2021.

The generics of Wegovy are possible to be released after 17 February, 2041.

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Jun 04, 2024
New Dosing Schedule(D-190)	Jul 21, 2026
New Indication(I-935)	Mar 08, 2027
New Patient Population(NPP)	Dec 23, 2025
New Chemical Entity Exclusivity(NCE)	Dec 05, 2022

Drugs and Companies using SEMAGLUTIDE ingredient

05 December, 2021

04 June, 2021

Method for weight management according to a dose escalation schedule; Method for weight management

SOLUTION;SUBCUTANEOUS